The U.S. jobs market powered on to more gains, as nonfarm payrolls rose 225k for January exceeding Wall Street estimates. While the unemployment rate walked higher to 3.6% in concert with the labor force participation rate rising +.2 percentage points to 63.4%. The improvement is thought to be attributed to the milder/warmer weather we experienced in January.
Every February 4th is World Cancer Day, the global uniting initiative led by the Union for International Cancer Control (UICC). By raising worldwide awareness, improving education and catalyzing personal, collective, and government action, they are working to reimagine a world where millions of preventable cancer deaths are saved and access to lifesaving cancer treatment and care is equal for all.
In honor of World Cancer Day, I had the distinct pleasure of interviewing Kyle Guse (pictured above), Chief Financial Officer of Seattle-based Atossa Therapeutics (NASDAQ: ATOS). a clinical-stage biopharmaceutical company developing novel, proprietary therapeutics and delivery methods for breast cancer and other breast conditions. They believe their innovative therapies and delivery methods can transform breast cancer treatment– with the goal of preventing breast cancer from developing in the first place to increase the odds of surviving for those who do develop this deadly disease. Mr. Guse has served as Chief Financial Officer, General Counsel and Secretary since January 2013. His experience includes more than 20 years of counseling life sciences and other rapid growth companies through all aspects of finance, corporate governance, securities laws, and commercialization. (READ COMPLETE STORY)
Guggenheim Securities, LLC initiated sell-side coverage with a BUY Rating & an associated $13/share price target on Neubase Therapeutics (NASDAQ: NBSE) after the close of the markets yesterday stating “NBSE’s PATrOL platform for the development of ASOs has the potential to address key limitations of current oligo therapeutics.” In short, NeuBase has developed a modular antisense peptide nucleic acid (PNA) platform with the capability to address rare genetic disease caused by mutant proteins with a single, cohesive approach. NeuBase has improved gene silencing therapies to include the advantages of synthetic approaches with the precision of antisense technologies. NeuBase is first addressing Huntington’s disease and myotonic dystrophy. Shares of NBSE are trading up +8.94% today at $6.46/share.